Erlotinib has proved to increase survival in patients with locally advanced or metastatic NSCLC where conventional chemotherapy regimens have failed. Non-smokers, women, Asians, patients with adenocarcinoma and with more than 10% of cells with expression of EGFR would be the best candidates for this treatment. It has not been proved to be effective as first line therapy.